Introduction
Cystic fibrosis (CF) is the most common lethal autosomal recessive disease in Caucasians, and is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene encoding a cAMP-dependent chloride channel. 1, 2 Mutations in CFTR lead to imbalanced ion transport across the airway epithelium, resulting in altered airway host defences, which are ultimately responsible for the mortality of CF patients. CFTR is 1480 amino acids long and contains two homologous regions each comprising six transmembrane loops, as well as two nucleotide-binding domains (NBD1 and 2) connected by a regulatory (R) domain. CFTR is known to be highly glycosylated at two asparagine residues on extracellular loop 4, and principally exists in both immature and mature-glycosylated forms. 3 Immature CFTR has a high content of mannose type oligosaccharides, and exists in the endoplasmic reticulum as a precursor that is transferred to the trans-Golgi network. During transit through this network the immature CFTR is converted into mature CFTR with the addition of complex carbohydrate chains containing polylactosaminoglycan sequences. 4 This glycosylation is both an indicator of CFTR maturation and is responsible for proper CFTR function. At least some functions of CFTR require correct localization to the apical membrane. Thus, the most common mutation causing CF (DF508-a deletion of a phenylalanine at position 508 in the NBD1 of CFTR) results in retention in the endoplasmic reticulum and degradation by the proteasome pathway. 5 Increasing the apical localization of DF508-CFTR at the cell membrane, for example by cooling, can partially restore chloride channel function. Thus, a combination of mature glycosylation and appropriate cellular localization is essential for the function of CFTR.
The airway epithelium is an important target for CF gene therapy. However, gene transfer is hindered by factors such as the overlying mucus layer, the low rate of endocytosis at the apical surface, passage through the nuclear pore complex and many other factors. Therefore, efficient gene transfer vectors are desired for CF gene therapy. Sendai virus (SeV) is a non-segmented negativestrand RNA virus, belonging to the family Paramyxoviridae. Because SeV infects and replicates in airway epithelial cells very efficiently, 6, 7 we have developed SeV as a potential gene transfer vector for CF gene therapy, and other diseases. We have generated a series of SeV vectors carrying the CFTR gene and examined SeV-mediated CFTR gene transfer both in vitro and in vivo. 8 However, there was no clear correlation between the CFTR expression levels estimated from the design of a series of the vectors and the observed CFTR function. In addition, cytotoxicity was observed in cells transduced by some types of SeV vector that may be related to CFTR overexpression. SeV is a cytoplasmic expression vector, and to the best of our knowledge there is no prior data confirming the correct localization and function of a complex transmembrane protein derived from a cytoplasmic vector. Indeed, given the importance of the correct sequence of glycosylation steps and transport to the apical membrane, we attempted to detect apically localized CFTR protein by immunohistochemistry. However, within the field in general, reliable detection of CFTR has been difficult to achieve and this was also the case in our hands. Therefore, we constructed a recombinant SeV vector, designated GFP-CFTR(HNL)-SeV/DF, in which the N terminus of CFTR was fused to the green fluorescent protein (GFP) gene allowing for detection by either GFP fluorescence or immunohistochemistry using anti-GFP antibodies. Previous studies have shown that GFP fused to the N terminus of CFTR neither affected chloride channel function, nor intracellular processing or the correct apical localization of CFTR. [9] [10] [11] [12] The fusion gene, GFP-CFTR, was inserted into the genome of the fusion (F) gene-deleted Sendai virus (SeV/DF) vector. 13 The SeV/DF vector is non-transmissible because the F gene that is essential for the penetration of SeV after attachment to the cell surface is deleted from its genome. We report here on the characterization of the GFP-CFTR fusion protein expressed by this SeV/DF vector both in vitro and in vivo.
Results

Construction of a SeV vector carrying the GFP-CFTR fusion gene, GFP-CFTR(HNL)-SeV/DF
We constructed the GFP-CFTR fusion gene, in which GFP was fused to the N terminus of CFTR using a 4 amino-acid linker sequence (K-R-R-A). This fusion gene (5.1 kb) is one of the longest transgenes carried by a SeV vector to date, 14 and was introduced at the junction between the hemagglutinin-neuraminidase (HN) and large protein (L) genes in the SeV/DF genome ( Figure 1 ).
The positioning was based on the wish to limit CFTR overexpression given the high efficiency of this system. There is a gradient in expression level (position effect) dependent on the location of the transgene within the SeV genome due to the polarity of transcription. Thus, transgene expression from the site between HN and L was expected to be about 10 times lower than that from the first locus (3 0 -terminus) of the vector genome. 15 The GFP-CFTR(HNL)-SeV/DF vector was generated successfully and propagated to high titers of more than 10 8 cell infectious units per ml in culture medium.
Size and glycosylation pattern of the SeV-derived GFP-CFTR fusion protein
To confirm the expression of GFP-CFTR fusion proteins, LLC-MK2 cells were transduced with a GFP-CFTR (HNL)-SeV/DF vector at MOIs of 1, 3 and 10. After 2 days, cells were harvested and analyzed by western blotting using an anti-GFP antibody. Two major GFPpositive proteins (190 and 170 kDa) were detected (Figure 2a) , which corresponded to the fully glycosylated mature and the core-glycosylated immature CFTR proteins, respectively.
We also analyzed the CFTR glycosylation pattern to confirm correct maturation of the protein. The mature and immature CFTR proteins are known to be distinguishable by means of differential sensitivity to glycosidases. Thus, the fully glycosylated mature CFTR protein is insensitive to Endo H and sensitive to PNGaseF. In Mature GFP-CFTR expression by Sendai virus vector H Ban et al contrast, the core-glycosylated immature CFTR protein is sensitive to both Endo H and PNGaseF. As expected, the 190 kDa protein was only sensitive to PNGaseF, while the 170 kDa protein was sensitive to both glycosidases ( Figure 2b ). These results showed that glycosylation of the GFP-CFTR fusion protein derived from GFP-CFTR(HNL)-SeV/DF was similar to that of the endogenous CFTR protein. 3, 4 Cellular localization of the GFP-CFTR protein expressed by SeV/DF vector in vitro Next, we analyzed the cellular localization of the GFP-CFTR fusion protein in polarized MDCK type I cells using confocal laser microscopy after transduction by GFP-CFTR(HNL)-SeV/DF or GFP-SeV/DF. In this experiment GFP-CFTR and GFP proteins were stained immunocytochemically using a primary anti-GFP antibody followed by an Alexa 488-conjugated secondary antibody. The GFP-CFTR fusion protein was localized both to the apical membrane and the cytoplasm (Figures 3b and e), whereas the GFP protein was only expressed in the cytoplasm (Figures 3a and d) . These findings suggest that the GFP-CFTR protein produced by the SeV/DF vector is trafficked to its appropriate cell membrane location.
Channel activity of the GFP-CFTR fusion protein produced by the SeV/DF vector
Fusion of GFP to the N terminus of CFTR has previously been shown not to effect CFTR function. 9 To confirm this we performed iodide efflux assays in A549 cells to assess the channel activity of GFP-CFTR derived from GFP-CFTR(HNL)-SeV/DF vector. A549 cells were used for several reasons: (1) very low or absence of CFTR expression, 16 (2) efficient loading with iodide tracer in the absence of passive leaking, (3) good response to forskolin stimulation and (4) efficient transduction by SeV. The vector produced a significant increase in iodide efflux compared to mock-transduced and control vector (SeV vector carrying the lacZ gene; LacZ-SeV) transduced cells (Figure 4) . Similar results were obtained in 293T cells (data not shown). These results showed that the GFP fused CFTR protein expressed by GFP-CFTR (HNL)-SeV/DF was biologically functional with respect to chloride channel activity.
In vivo transduction and localization of GFP-CFTR protein by the SeV/DF vector
We next investigated the localization of the SeV vectorderived GFP-CFTR protein in mouse nasal tissue in vivo and compared this to the expression generated after transduction with GFP-SeV/DF control vectors. Both vectors transduced nasal ciliated epithelial cells (Figures  5a-f) . Strong GFP fluorescence was observed in mice inoculated with GFP-SeV/DF, and the GFP protein was localized throughout the cytoplasm of the epithelial cells (Figures 5a and d) . In contrast, an overall weaker but highly reproducible GFP signal was detected in mice inoculated with GFP-CFTR(HNL)-SeV/DF, which in part was localized at the apical surface of the nasal ciliated (Figures 5b and e) . The difference in signal intensity would be mainly related to the position effect. 15 These findings suggest that the GFP-CFTR(HNL)-SeV/DF vector can direct the production of a membrane localized GFP-CFTR protein in vivo.
Discussion
We have previously shown efficient expression of reporter genes in respiratory epithelium cells after SeV infection 6, 7 and have, therefore, begun to assess its potential use for CFTR gene transfer. Because CFTR is a complex transmembrane protein requiring several glycosylation steps during intracellular processing and transit to the apical membrane and SeV is a cytoplasmic expression system with the attendant possibility that expressed proteins will not be subjected to conventional intracellular processing, we sought evidence for the appropriate production of correctly glycosylated, functional, cell surface-localized CFTR. Here, we demonstrate using a GFP tag that SeV vector-derived CFTR protein is fully glycosylated, appropriately localized at the cell surface both in vitro and in vivo and retained chloride channel function. Therefore, this type of high expression vector may be suitable for use in a program aimed at developing CF gene therapy.
To date viral vectors such as AdV and AAV have been developed for CF gene therapy. However, a number of limitations in their use have become apparent. While, AdV carrying the CFTR gene, with or without a tag sequence, can express the mature-glycosylated CFTR, 17 its receptor is predominantly localized to the basolateral surface of the conducting airway epithelium. This, in addition to the lumenal glycocalyx also being a further barrier, 18 means that transduction from the apical surface using AdV is inefficient. 19 With regards to AAV, its limited gene packaging capacity causes difficulties with low CFTR expression related to the need to resort to the weak endogenous ITR promoter, 20 although AAV has the advantage of potential long-term expression of the transgene.
Compared with these vectors, SeV has a number of advantages for CFTR gene delivery. (i) SeV is able to penetrate the overlying mucus layer with relatively little loss of activity and transduce the airway epithelium efficiently, (ii) the expression level of the transgene can, within limits, be regulated by changing the position of the inserted transgene, 15 and (iii) the gene packaging capacity of SeV is large enough to accommodate the CFTR gene.
Recently, respiratory syncytial virus and human parainfluenza virus, belonging to the same Paramyxoviridae family as SeV, were suggested as gene transfer vectors for CFTR. 21, 22 However, these viruses are known to be pathogenic to humans, unlike SeV where no human pathogenicity has been reported. Moreover, we have developed a series of single, double and triple gene(s)-deleted SeV vectors, 13, [23] [24] [25] [26] by using packaging cell lines that express the respective proteins encoded by the deleted gene(s). These vectors show efficient transduction ability and transgene expression in a variety of cell lines and primary cells in vitro. For example, the F-deletion makes the SeV vector non-transmissible, the M-deletion renders the vector incapable of directing the formation of viral particles in infected cells, while the HN-deletion may reduce the host immune response against the SeV vector. However, many types of SeV vectors show transient (days to weeks) transgene expression.
14 Thus, for clinical use for a lifelong disease such as CF, further improvements in the SeV vector that either allow long-term gene expression, or repeated administration would be important.
Building on the known strength of SeV to transfect the airway epithelium efficiently because of the F and HN proteins expressed on its surface, we have developed Mature GFP-CFTR expression by Sendai virus vector H Ban et al simian immunodeficiency virus-based lentivirus vectors pseudotyped with these SeV F and HN proteins. Efficient gene delivery to airway epithelial cells can be achieved using this vector, 27 as well as long-lasting reporter gene expression in simian immunodeficiency virus vectoradministered mice. 28, 29 In conclusion, CFTR expressed by the SeV/DF vector was fully glycosylated, localized to the apical surface and biologically functional. Thus, the SeV vector is a candidate vector for CF gene therapy, as well as a potentially useful tool with which to study CFTR function both in vitro and in vivo.
Materials and methods
Cells and viruses
LLC-MK2 (monkey kidney) and MDCK type I (dog kidney) cells were grown at 37 1C in minimal essential medium (MEM: Gibco-BRL, Rockville, MD, USA) supplemented by 10% heat-inactivated fetal bovine serum (FBS). Wild-type SeV carrying the b-galactosidase (lacZ) gene inserted before the NP ORF (lacZ-SeV) 30 was grown in 10-day-old embryonated chicken eggs. 31 SeV/DF vector carrying the GFP-CFTR gene positioned between the HN and L genes was termed GFP-CFTR(HNL)-SeV/DF, and was amplified in the LLC-MK2 cell line that expresses the F protein (LLC-MK2/F7). 13 
Plasmid construction
For the construction of a genomic cDNA of SeV/DF carrying the GFP-CFTR gene between the HN and L genes (pGFP-CFTR(HNL)-SeV/DF), we utilized the full-length genomic cDNA of wild-type SeV (pSeV(+) (HNL)), 14 in which a NotI restriction site designed for the insertion of gene of interest between the HN and L genes was introduced. The 4.3-kb AgeI fragment containing the HN and L genes of pSeV(+)(HNL) was substituted by the 4.3-kb AgeI fragment of full-length genomic cDNA of SeV/DF (pSeV/DF) 13 to generate pSeV(HNL)/DF. The GFP-CFTR fusion gene was prepared as follows. The CFTR gene was amplified by PCR using a pair of AscItagged primers: (5 0 -GCGGCGCGCCATGCAGAGGTCG CCTCTGGAAAAGG-3 0 ) and (5 0 -GCGGCGCGCCTCTAA AGCCTTGTATCTTGCACC-3 0 ). The amplified fragment was digested with AscI and inserted into the vector pAC116 15 to generate pAC116-CFTR. The GFP gene was amplified using two specific primers GFPF (5 0 -GCCAT GGTGAGCAAGGGCGAGGAGCTG-3 0 ) and GFPR696 (5 0 -CTTGTACAGCTCGTCCATGCCG-3 0 ) with pSeV 18+ GFP 30 as a template. The GFP fragment was inserted into the PmeI restriction site of pAC116-CFTR to generate pAC116-GFPCFTR. The GFP-CFTR fusion gene prepared by digestion of pAC116-GFPCFTR with NotI was cloned into the NotI site of pSeV(HNL)/DF, thus generating pGFP-CFTR(HNL)-SeV/DF. For the construction of the expression plasmid of GFP-CFTR, the GFP-CFTR gene was prepared by digesting pGFP-CFTR(HNL)-SeV/DF with NotI, blunted by Pfu DNA polymerase (Promega), and cloned into the pCAGGS, 32 thus generating pCAGGS-GFP-CFTR.
Recovery of GFP-CFTR(HNL)-SeV/DF vector
Recovery and propagation of the GFP-CFTR(HNL)-SeV/DF vector was carried out according to the method described previously. 23, 26 Briefly, approximately 10 7 LLC-MK2 cells seeded in a 10 cm diameter dish were infected with psoralen-and long-wave UV-treated 33 vTF7-3 at an MOI of two. After 1 h of incubation at room temperature, the cells were washed with MEM and transfected with the plasmid mixture described below. For transfection, plasmids pGEM-NP (4 mg), pGEM-P (2 mg), pGEM-L (4 mg), 27 pGEM-F (4 mg), 26 and the SeV cDNA plasmid pGFP-CFTR(HNL)-SeV/DF (12 mg) were suspended in 200 ml of OptiMEM (Gibco-BRL, Rockville, MD, USA) with 110 ml of Superfect transfection reagent (Qiagen GmbH, Hilden, Germany). After the mixture was allowed to stand at room temperature for 15 min, it was added to the prepared LLC-MK2 cells in 3 ml of OptiMEM containing 3% FBS and the cells were further cultured for 3 h. The cells were then washed twice with MEM, and cultured for 24 h in MEM containing cytosine b-D-arabinofuranoside (AraC; 40 mg ml
À1
) and trypsin (7.5 mg ml
). Approximately 10 7 LLC-MK2/F7/A cells expressing the F protein were suspended in MEM containing AraC (40 mg ml
) and trypsin (7.5 mg ml À1 ), and layered onto the transfected cells, 26, 33 and cultured at 37 1C for an additional 48 h. The recovered vector in the culture supernatants was propagated using the LLC-MK2/F7/A cells.
RT-PCR
Total viral RNA from GFP-CFTR(HNL)-SeV/DF was isolated using a QIAamp viral RNA mini kit (Qiagen). RT-PCR was performed in a one-step process using the 
Western blot analysis
LLC-MK2 cells (10 6 ) grown in 6-well plates were infected with GFP-CFTR(HNL)-SeV/DF at MOIs of 1, 3 and 10, and cultured at 37 1C under 5% CO 2 for 2 days. Cells were washed twice and harvested in cold phosphatebuffered saline(-), followed by centrifugation at 6000 r.p.m. for 3 min at 4 1C, and lysed in 100 ml lysis buffer (150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 0.1% Triton X-100, 20 mM Tris-HCl (pH 7.5) containing 5 mg ml À1 leupeptin, 5 mg ml À1 pepstatin and 5 mg ml À1 aprotinin). Samples that were first homogenized using Qiashredder column (Qiagen GmbH, Hilden, Germany) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 7.5% gel and electrophoretically transferred onto polyvinylidine difluoride (PVDF) membranes. The membrane was blocked with 100% Block ACE for 1 h at 4 1C and then incubated with anti-GFP primary antibody (1:2000) (Invitrogen, Corp., Carlsbad, CA, USA), followed by incubation with secondary antibody (anti-rabbit IgG conjugated with HRP, 1:5000). The GFP-CFTR Mature GFP-CFTR expression by Sendai virus vector H Ban et al protein on the membrane was detected by a chemiluminescence method (ECL western blotting detection reagents; Amersham Biosciences, Uppsala, Sweden).
Glycosylation analysis
LLC-MK2 cells (10 6 ) grown in 6-well plates were infected with GFP-CFTR(HNL)-SeV/DF at an MOI of three and cultured for 2 days. Cells were harvested in cold phosphate-buffered saline(-), followed by centrifugation at 6000 r.p.m. for 3 min at 4 1C, and lysed in 100 ml lysis buffer (150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 0.1% Triton X-100, 20 mM Tris-HCl (pH 7.5) containing 5 mg ml À1 leupeptin, 5 mg ml À1 pepstatin and 5 mg ml À1 aprotinin) and homogenized using a Qiashredder column. The samples were digested with endoglycosidase H (Endo H) (New England Biolabs, Beverly, MA, USA) or peptide N-glycosidase F (PNGase F) (New England Biolabs, Beverly, MA, USA) for 3 h at 37 1C. The reaction mixture was analyzed by western blotting using anti-GFP serum (Invitrogen) as described above.
Confocal microscopy
MDCK type I cells were transduced with GFP-CFTR (HNL)-SeV/DF or GFP-SeV/DF at an MOI of 2 and cultured for 7 days. Cells were then fixed with 100% MeOH and incubated with anti-GFP antibody (1:2000) (Invitrogen) and Alexa Fluor 488 goat anti-rabbit IgG (H+L) (1:5000) (Molecular Probes Inc., Engene, OR, USA). The cell surface membranes were visualized with EZ-Link Sulfo-NHS-SS-Biotin (Pierce, Rockford, IL, USA) and cells were examined by conventional confocal microscopy.
Iodide efflux assay
A549 cells were transduced with mock-vector, GFP-CFTR(HNL)-SeV/DF or lacZ-SeV vector at an MOI of five and cultured for 2 days. CFTR chloride channel activity was assayed by measuring the rate of 125 iodide efflux essentially as described previously. 34 The 125 iodide efflux rates were normalized to the time of forskolin/ IBMX addition (time 0). Curves were constructed by plotting rates of 125 iodide efflux against time. To reflect the cumulative levels of 125 iodide efflux following agonist-stimulation, all comparisons are based on areas under the time-125 iodide efflux curves. The area under the curve was calculated by the trapezium rule. Experiments were carried out in duplicate (n ¼ 6 wells/group/ experiment).
In vivo gene transfer to the murine nasal cavity
Adult BALB/cA mice (Charles River, Yokohama, Japan) weighing 20-25 g were anesthetized with ketamine and medetomidine. SeV vectors (10 7 cell infectious units) were administered intranasally in a 0.1 ml volume over 80 min. Three days after administration, the nasal cavity was removed and GFP fluorescence studied by fluorescence stereoscopic microscopy. For fluorescence microscopic analysis, the removed nasal cavity was fixed in 4% formaldehyde at room temperature for 2 h, decalcified with 0.24 M EDTA solution at room temperature for 5 days, and transferred into 30% sucrose overnight. The tissue was embedded in Tissue Mount (Chiba Medical, Chiba, Japan), and sectioned at 10 mm thicknesses using a microtome. Sections were observed by fluorescence microscopy. All animal experiments were carried out according to the protocols approved by the Institutional Committee for Animal Experiments and by the Institutional Committee for Recombinant DNA Experiments, DNAVEC Corporation. The experiments were carried out in accordance with recommendations for the proper care and use of laboratory animals and according to The Law (No 105) and Notification (No 6) of the Japanese Government.
Statistical analysis
Statistical analysis was performed using ANOVA followed by post hoc analysis. The null hypothesis was rejected at Po0.05.
